• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Summit Therapeutics Inc.

    2/23/26 4:58:58 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SMMT alert in real time by email
    S-8 1 d98529ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on February 23, 2026

    Registration No. 333-   

     

     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    SUMMIT THERAPEUTICS INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   37-1979717

    (State or Other Jurisdiction of

    Incorporation or Organization)

     

    (I.R.S. Employer

    Identification No.)

    601 Brickell Key Drive, Suite 1000

    Miami, FL

    (Address of Principal Executive Offices)

    2020 Stock Incentive Plan

    (Full Title of the Plans)

    Robert Duggan

    Co-Chief Executive Officer

    Summit Therapeutics Inc.

    601 Brickell Key Drive, Suite 1000

    Miami, FL 33131

    (305) 203-2034

    Mahkam Zanganeh

    Co-Chief Executive Officer

    Summit Therapeutics Inc.

    601 Brickell Key Drive, Suite 1000

    Miami, FL 33131

    (305) 203-2034

    (Name, Address and Telephone Number, Including Area Code, of Agent for Service)

    Copies to:

    Adam Finerman, Esq.

    Baker & Hostetler LLP

    45 Rockefeller Plaza

    New York, NY 10111

    Telephone: (212) 589-4233

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☒    Accelerated filer   ☐
    Non-accelerated filer   ☐    Smaller reporting company   ☐
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     
     


    EXPLANATORY NOTE

    Summit Therapeutics Inc. (the “Registrant”) is filing this registration statement on Form S-8 (the “Registration Statement”) with the Securities and Exchange Commission (the “Commission”) for the purpose of registering an aggregate of 6,400,000 additional shares of Common Stock that were added to the shares authorized for issuance under, and in accordance with, the Registrant’s Amended and Restated 2020 Stock Incentive Plan (the “Plan”), effective January 1, 2026. The Registrant previously registered shares of Common Stock for issuance under the Plan under Registration Statements on Form S-8 filed with the Commission on October  5, 2020 (File No. 333-249313), April  6, 2022 (File No. 333-264163), May  1, 2024 (File No. 333-279024) and May  19, 2025 (File No. 333-287402). Pursuant to General Instruction E to Form S-8 this Registration Statement hereby incorporates by reference the contents of the Registration Statements referenced in the preceding sentence.

    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

    The information specified in Item 1 and Item 2 of Part I of Form S-8 is omitted from this Registration Statement in accordance with the provisions of Rule 428 under the Securities Act. The documents containing the information specified in Item 1 and Item 2 of Part I of Form S-8 will be delivered to the participants in the plan covered by this Registration Statement as specified by Rule 428(b)(1) under the Securities Act.

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3. Incorporation of Documents by Reference.

    The Registrant is subject to the informational and reporting requirements of Sections 13(a), 14, and 15(d) of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), and in accordance therewith files reports, proxy statements and other information with the Securities and Exchange Commission (the “Commission”). The following documents, which have been filed with the Commission, are incorporated in this Registration Statement by reference:

     

      (a)

    The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Commission on February 23, 2026;

     

      (b)

    The Registrant’s Current Reports on Form 8-K filed on January  29, 2026; and

     

      (c)

    The description of the Registrant’s Common Stock contained on the Registrant’s registration statement on Form 8-K dated September 18, 2020, including any amendment or report filed for the purpose of updating such description.

    All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items), prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of the filing of such documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for the purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.


    Item 8. Exhibits.

     

    Exhibit     
    Number   

    Exhibit Description

      4.1    Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the Commission on September 18, 2020)
      4.2    Amendment to Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the Commission on July 29, 2022)
      4.3    Amendment No. 2 to Restated Certificate of Incorporation, dated January  19, 2023 (incorporated by reference to Exhibit 5.1 to the Registrant’s Current Report on Form 8-K filed with the Commission on January 20, 2023)
      4.4    Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K, filed with the Commission on September 18, 2020)
      5.1    Opinion of Baker & Hostetler LLP
     23.1    Consent of PricewaterhouseCoopers LLP, independent registered public accounting firm for the Registrant
     23.2    Consent of Baker & Hostetler LLP (included in Exhibit 5.1)
     24.1    Power of Attorney (included on signature page)
     99.1    Amended and Restated 2020 Stock Incentive Plan, dated October  12, 2023 (incorporated by reference to Exhibit 99.1 to the Registrant’s Registration Statement on Form S-8 (File No.  333-279024), filed with the Commission on May 1, 2024)
     99.2    Form of Option Award under 2020 Stock Incentive Plan (incorporated by reference to Exhibit 99.2 to the Registrant’s Registration Statement on Form S-8 (File. No. 333-287402) filed with the Commission on May 19, 2025)
     99.3    Form of Restricted Stock Unit Agreement under 2020 Stock Incentive Plan (incorporated by reference to Exhibit 10.29 to the Registrant’s Current Report on Form 8-K, filed with the Commission on September 29, 2020)
    107    Filing Fee Table


    SIGNATURES

    Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, on February 23, 2026.

     

    SUMMIT THERAPEUTICS INC.
    By:   /s/ Robert W. Duggan
      Robert W. Duggan
      Co-Chief Executive Officer and Executive Chairman (Principal Executive Officer)
    By:   /s/ Mahkam Zanganeh
      Dr. Mahkam Zanganeh
      Co-Chief Executive Officer, President and Director (Principal Executive Officer)

    SIGNATURES AND POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Robert W. Duggan, Mahkam Zanganeh and Manmeet Soni, and each one of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in their name, place, and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities held on the dates indicated.

     

    Name

      

    Position

     

    Date

    /s/ Robert W. Duggan

    Robert W. Duggan

      

    Co-Chief Executive Officer and Executive Chairman

    (Principal Executive Officer)

      February 23, 2026

    /s/ Mahkam Zanganeh

    Dr. Mahka m Zanganeh

      

    Co-Chief Executive Officer, President and Director

    (Principal Executive Officer)

      February 23, 2026

    /s/ Manmeet S. Soni

    Manmeet S. Soni

      

    Chief Operating Officer, Chief Financial Officer and Director

    (Principal Financial Officer)

      February 23, 2026

    /s/ Bhaskar Anand

    Bhaskar Anand

      

    Head of Finance and Chief Accounting Officer

    (Principal Accounting Officer)

      February 23, 2026

    /s/ Robert F. Booth

    Dr. Robert F. Booth

       Director   February 23, 2026

    /s/ Alessandra Cesano

    Alessandra Cesano

       Director   February 23, 2026


    /s/ Kenneth Clark

    Kenneth Clark

       Director   February 23, 2026

    /s/ Jeff Huber

    Jeff Huber

       Director   February 23, 2026

    /s/ Mostafa Ronaghi

    Mostafa Ronaghi

       Director   February 23, 2026

    /s/ Yu Xia

    Dr. Yu Xia

       Director   February 23, 2026
    Get the next $SMMT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SMMT

    DatePrice TargetRatingAnalyst
    5/22/2026Buy → Neutral
    H.C. Wainwright
    4/8/2026$45.00Buy
    Stifel
    3/16/2026$15.00Buy → Hold
    Jefferies
    12/17/2025$18.00Underweight → Equal Weight
    Barclays
    11/18/2025Peer Perform
    Wolfe Research
    9/17/2025$13.00Underweight
    Barclays
    9/4/2025$40.00Buy
    Guggenheim
    8/19/2025$21.00Neutral
    Piper Sandler
    More analyst ratings

    $SMMT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Xia Yu bought $9,999,983 worth of shares (533,617 units at $18.74) (SEC Form 4)

    4 - Summit Therapeutics Inc. (0001599298) (Issuer)

    10/23/25 9:06:30 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Co-Chief Executive Officer Duggan Robert W bought $499,983 worth of shares (26,680 units at $18.74) and was granted 14,247,597 shares, increasing direct ownership by 3% to 570,073,879 units (SEC Form 4)

    4 - Summit Therapeutics Inc. (0001599298) (Issuer)

    10/23/25 4:08:30 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Co-Chief Executive Officer Zanganeh Mahkam was granted 14,247,597 shares and bought $499,983 worth of shares (26,680 units at $18.74) (SEC Form 4)

    4 - Summit Therapeutics Inc. (0001599298) (Issuer)

    10/23/25 4:06:32 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SMMT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Summit Therapeutics downgraded by H.C. Wainwright

    H.C. Wainwright downgraded Summit Therapeutics from Buy to Neutral

    5/22/26 8:27:33 AM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stifel initiated coverage on Summit Therapeutics with a new price target

    Stifel initiated coverage of Summit Therapeutics with a rating of Buy and set a new price target of $45.00

    4/8/26 8:38:26 AM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Summit Therapeutics downgraded by Jefferies with a new price target

    Jefferies downgraded Summit Therapeutics from Buy to Hold and set a new price target of $15.00

    3/16/26 8:36:55 AM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SMMT
    SEC Filings

    View All

    Summit Therapeutics Inc. filed SEC Form 8-K: Other Events

    8-K - Summit Therapeutics Inc. (0001599298) (Filer)

    6/3/26 8:01:16 AM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Summit Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Summit Therapeutics Inc. (0001599298) (Filer)

    6/1/26 6:57:20 AM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Summit Therapeutics Inc.

    10-Q - Summit Therapeutics Inc. (0001599298) (Filer)

    4/30/26 5:00:54 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SMMT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Accounting Officer Anand Bhaskar

    4 - Summit Therapeutics Inc. (0001599298) (Issuer)

    1/12/26 4:01:39 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Co-Chief Executive Officer Zanganeh Mahkam

    4 - Summit Therapeutics Inc. (0001599298) (Issuer)

    1/6/26 7:52:54 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Co-Chief Executive Officer Duggan Robert W

    4 - Summit Therapeutics Inc. (0001599298) (Issuer)

    1/6/26 7:50:20 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SMMT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China

    Ivonescimab Plus Chemotherapy Reduced the Risk of Death by 34% Compared to Tislelizumab Plus Chemotherapy; Hazard Ratio 0.66 First Regimen to Achieve a Statistically Significant and Clinically Meaningful Overall Survival Benefit over an anti-PD-(L)1 Antibody Combined with Chemotherapy in a Phase III Clinical Trial in 1L NSCLC Tolerable Safety Profile Consistent with Prior Clinical Trial Results Simultaneous Publication of Latest Ivonescimab HARMONi-6 Results in The Lancet Summit Conference Call to Be Held at 7:00 a.m. ET on Monday, June 1, 2026 Summit Therapeutics Inc. (NASDAQ:SMMT) today announced positive overall survival (OS) results from the Phase III HARMONi-6 trial, conducte

    5/31/26 9:06:00 AM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Encouraging Global Phase II Ivonescimab Data in First-Line Metastatic Colorectal Cancer Presented at ASCO 2026

    Promising Data Further Support Continued Expansion of Ivonescimab Clinical Development in mCRC Overall Study Population Achieved ORR of 70.8% and DCR of 100.0%; Responses Consistent Across Ivonescimab Dose Levels Combined with Chemotherapy Acceptable and Manageable Safety Profile for Ivonescimab Regimen; No New Safety Signals Observed Summit Therapeutics Inc. (NASDAQ:SMMT) today presented new results from the AK112-206 trial (NCT05382442), a global, open-label, multicenter Phase II study in first-line metastatic colorectal cancer (mCRC) co-sponsored by Summit and Akeso, featuring the novel, potential first-in-class investigational bispecific antibody ivonescimab. The data were present

    5/30/26 8:00:00 AM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters Clinic

    Issued on behalf of GT Biopharma, Inc. SAN FRANCISCO, May 18, 2026 /CNW/ -- USA News Group News Commentary — For more than two decades, B7-H3 sat on the shortlist of theoretically perfect cancer drug targets that nobody could quite figure out how to hit. The protein is broadly overexpressed across some of the most common — and most lethal — solid tumors, including prostate, lung, breast, ovarian, head and neck, and pancreatic cancers. It is largely absent from healthy tissue. It correlates with poor prognosis. On paper, it has every quality a drug developer wants. In practice, three B7-H3-targeting antibody-drug conjugates have entered the clinic, and none have yet been approved.[1] That is

    5/18/26 2:22:00 PM ET
    $GSK
    $GTBP
    $IDYA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $SMMT
    Financials

    Live finance-specific insights

    View All

    Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China

    Ivonescimab Plus Chemotherapy Reduced the Risk of Death by 34% Compared to Tislelizumab Plus Chemotherapy; Hazard Ratio 0.66 First Regimen to Achieve a Statistically Significant and Clinically Meaningful Overall Survival Benefit over an anti-PD-(L)1 Antibody Combined with Chemotherapy in a Phase III Clinical Trial in 1L NSCLC Tolerable Safety Profile Consistent with Prior Clinical Trial Results Simultaneous Publication of Latest Ivonescimab HARMONi-6 Results in The Lancet Summit Conference Call to Be Held at 7:00 a.m. ET on Monday, June 1, 2026 Summit Therapeutics Inc. (NASDAQ:SMMT) today announced positive overall survival (OS) results from the Phase III HARMONi-6 trial, conducte

    5/31/26 9:06:00 AM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2026

    Overall Survival Data to be Featured at ASCO 2026 Plenary Session as Late-Breaking Abstract from HARMONi-6, a Phase III Study in 1L Squamous NSCLC in China Update Conference Call to be Held on June 1, 2026 after ASCO Plenary Session HARMONi-3 Squamous Cohort of Global Phase III 1L NSCLC Study: Final PFS Data Expected in Second Half of 2026 with Interim OS Analyses Planned HARMONi-3 Non-Squamous Cohort of Global Phase III 1L NSCLC Study: PFS Data Expected in the First Half 2027 Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on clinical and operational progress for the first quarter ended March 31, 2

    4/30/26 4:32:00 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2025

    HARMONi-3 Squamous Cohort of Global Phase III 1L NSCLC Study: Interim PFS Analysis Planned in Q2 2026; Final PFS and Interim OS Data Planned in Second Half of 2026 HARMONi-3 Squamous Cohort Enrollment Screening Has Been Completed Phase III ILLUMINE Study in 1L PD-L1 Positive R/M HNSCC Sponsored by Cooperative Group, GORTEC, to Initiate; First Patient Expected in Early Q2 2026 US FDA Accepts BLA Filing Based on HARMONi Study; PDUFA Goal Action Date of November 14, 2026 First Patient Dosed in Revolution Medicines Clinical Trial Collaboration Evaluating Ivonescimab in Combination with RAS(ON) Inhibitors in RAS Mutant Tumors GSK Collaboration Clinical Trials Evaluating Ivonescimab in

    2/23/26 4:05:00 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SMMT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Summit Therapeutics Inc.

    SC 13D/A - Summit Therapeutics Inc. (0001599298) (Subject)

    9/13/24 5:54:25 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Summit Therapeutics Inc. (Amendment)

    SC 13D/A - Summit Therapeutics Inc. (0001599298) (Subject)

    3/13/23 4:51:59 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Summit Therapeutics Inc. (Amendment)

    SC 13D/A - Summit Therapeutics Inc. (0001599298) (Subject)

    2/16/23 4:01:07 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SMMT
    Leadership Updates

    Live Leadership Updates

    View All

    Robert LaCaze, Innovative Growth-Driver in Oncology, Joins Summit Therapeutics as Chief Commercial Officer

    Mr. LaCaze Brings Over 35 Years of Executive Leadership Experience in the Biopharmaceutical Industry Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced that Robert LaCaze has joined Summit Therapeutics as Chief Commercial Officer, reporting to Manmeet S. Soni, Chief Operating Officer and Chief Financial Officer, effective immediately. Robert W. Duggan and Dr. Maky Zanganeh, Co-CEOs of Summit Therapeutics, stated, "Robert's extensive experience and proven track record in the oncology space make him an exceptional addition to our team. His leadership will be instrumental as we seek to bring ivonescimab to patients in need. We are truly excited to have

    3/17/25 4:24:00 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Summit Therapeutics Appoints Jeff Huber, Transformational Google and GRAIL Executive, to its Board of Directors

    Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced that Jeff Huber has been appointed to its Board of Directors, effective immediately. "It is an honor to add Jeff Huber to our excellent, diverse group of board members," stated Robert W. Duggan, Chairman and Chief Executive Officer of Summit. "Jeff's executive leadership experience in healthcare and technology and his countless accomplishments evidence his ability to translate what's possible into transformational success. As we seek to change the standard of care for solid tumors based on the potential of ivonescimab, we are thrilled to supplement our outstanding leadership team with a board member

    6/27/24 4:15:00 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors

    Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced that Mostafa Ronaghi, PhD, has been appointed to its Board of Directors, effective immediately. "We are excited to add Dr. Ronaghi to complement our excellent group of current board members," stated Robert W. Duggan, Chairman and Chief Executive Officer of Summit. "Mostafa has valuable experience in translating innovative concepts in genomics and sequencing that ultimately lead to advancements in patient care through his work at Illumina, Grail, and his continuing ventures. As we intend to maximize the potential of ivonescimab, we are excited to add the acumen and expertise that Mostafa can bring to

    4/11/24 4:30:00 PM ET
    $ILMN
    $SMMT
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations